Add Testosterone replacement therapy and cardiovascular risk Nature Reviews Cardiology

Adrianne Stonge 2026-04-03 07:12:19 +08:00
commit 021f25bc71

@ -0,0 +1,8 @@
<br>
<br>Several meta-analyses of published aggregate data have investigated the cardiovascular safety of testosterone treatment in men. We have also identified and reported frequencies of stable angina, peripheral vascular disease, aortic aneurysm, and aortic dissection, which have not been reported by any previous meta-analysis.5, 20, 21, 22, 28, 57, 58, 59 None of the cardiovascular event subtypes were significantly more common in patients assigned to [testosterone for sale](https://asiannearby.com/@rodgerhibbs49) treatment than in patients assigned to placebo. The small total number of deaths within our IPD analysis precluded a meaningful evaluation of the impact of testosterone treatment on mortality; furthermore, there was little available data evaluating the cardiovascular safety of testosterone beyond a 12-month duration of administration. In this systematic review and meta-analysis, placebo-controlled trials evaluating the effects of at least 3 months of [testosterone purchase](https://mkhonto.net/@annmccaffrey4?page=about) treatment in men with low testosterone were considered for inclusion. Conversely, testosterone treatment increases haematocrit, might lower high-density lipoprotein (HDL) cholesterol, and some studies have observed increased cardiovascular event risk. However, no trials of [purchase testosterone](http://8.131.93.145:54082/ottocheyne0153/2734123/wiki/5-Ways-Testosterone-Can-Impact-Your-Energy-Levels) replacement therapy published to date were designed or adequately powered to assess cardiovascular events; therefore, the cardiovascular safety of this therapy remains unclear.
Worldwide prescribing of testosterone for hypogonadism is increasing;2 however, conflicting messages on [buy testosterone](https://nonstopvn.net/@juanacarlin953?page=about) safety might have caused variations in treatment among patients. The secondary objective of this IPD analysis was to assess the physiological effects of testosterone treatment. To assess the effect of studies for which IPD were not available, we extracted appropriate aggregate study-level data and incorporated them alongside the IPD using two-stage IPD random-effect meta-analyses.64 Our aggregate meta-analysis suggested that outcome data were not significantly discrepant between our IPD and non-IPD studies. In view of the lack of consistent cardiovascular event classification, adjudication, or reporting within trials, we did a masked analysis of each individual adverse event by two independent clinicians to classify cardiovascular events from all IPD studies objectively. However, no overall association was observed between cardiovascular events and either free or total serum [buy testosterone online no prescription](http://139.196.82.227:3000/chloechitwood9) at baseline or during [buy testosterone injections](https://lawrencewilbert.com/read-blog/36877_testosterone-what-it-does-and-doesn-039-t-do.html) treatment.
For patients with persistent symptoms, surgical correction offers a definitive and long-lasting solution. This condition may develop during puberty, aging, medication use, or underlying health disorders. Gynecomastia results from a hormonal imbalance between testosterone and estrogen, leading to proliferation of glandular chest tissue. While the condition is benign, it can have a significant psychological impact, often leading patients to seek surgical correction. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein.
The PRAC further considered that the risks of effects on the heart and [sportseibt.de](https://sportseibt.de/antjepawsey695) circulation, and any potential mechanisms for such effects should continue to be monitored, and information from ongoing studies should be provided as part of the next regular safety review (to which these medicines, like all medicines in the EU, are subject). However, further studies are warranted to elucidate the risks of TRT in patients with significant CV risk factors and those with prior history of CV events. The results are very reassuring in that [buy testosterone gel online](https://links.gtanet.com.br/carolyndenee) replacement does not increase overall cardiovascular risk in this group of patients with symptomatic hypogonadism and low testosterone level. A total of 5,246 men aged years with pre-existing or high risk of cardiovascular disease, symptoms of hypogonadism, and testosterone levels Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using [buy testosterone booster](http://8.138.187.132:3000/thaliaallred75/thalia2000/wiki/The-Guys%27-Guide-to-Carbohydrates-and-TRT) for hypogonadism.
(4) Studies assessing the pre-specified primary or secondary outcomes of interest. The steroid hormone [buy testosterone steroids](http://47.99.119.173:13000/valencia147841) is fundamental to male physical development and sexual behaviour. We searched major electronic databases (MEDLINE, Embase, Science Citation Index, and CENTRAL), clinical trial registries, and contacted clinical experts. [testosterone buy online](http://139.196.82.227:3000/chloechitwood9) treatment is most often given to men aged 4065 years.
Quest offers three tiers of health profile tests Basic, Comprehensive, and Elite depending on the breadth of health insights you are most interested in. This test may be right for you if you are looking to go beyond basic, routine lab work and want a deeper health snapshot to help guide conversations with your doctor and make informed wellness decisions. After you have received your results, you have the ability to discuss them with an independent healthcare provider at no extra cost.
<br>